Bsense Bio Therapeutics
Neuropathic Pain Treatment
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Bsense Bio Therapeutics | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2018 | "1-10" |
Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. The company is pioneering a novel approach that targets multiple pain-related mechanisms using a single compound to achieve greater efficacy and safety.
Bsense Bio’s approach is based on the targeting of two cation channels, a ligand-gated and a voltage-gated potassium channel (TRPV1 and Kv7.2/3, respectively), which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in pain signaling.
Bsense is currently assessing in depth the specificity and selectivity in vitro of three lead compounds with the purpose of progressing into in vivo safety and efficacy studies. In addition, the company is performing structural activity relation studies to assess whether they can improve the compounds’ characteristics to achieve a backup compound series.
The company is financed by Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation (JJDC), and the Israel Innovation Authority (IIA). Bsense Bio Therapeutics was founded at the FutuRx biotech incubator.